actually quarter was fine-it was the guidance (lower and below street) and the shit show in the sales effort. And you know, that other thing the elephant in the room...begins with an o, ends with an s? Here's your clue-VERY important to most Docs and all patients??????????
What is the trial that led to that "superiority" claim was bogus and manufactured? What if the FDA was " Hoodwinked?" Would that matter?
The trial was seriously flawed, thus the results are bogus. Talk to a few SCS KOL's and listen to what the ones who are not paid "Nevro Whores" say....very enlightening!
what if the "clinical data" results were coerced and bear little resemblance to "real world outcomes"
Looks like your options took the same path as Nevro's long term real world outcomes. In the theoretical world Nevro is still worth $90 per share, unfortunately the real world is not as kind and it's tanking.
This is the fault of the DSMs. Obviously they’re not executing the simple strategy that Rami has set forth. Really sad that the sales force is so incompetent.
who wins the patent infringement lawsuit? How long does the CEO have before the Board pulls the plug?
